Professor
YANG Xinyi
Source:
time：2021-12-01
Views：
Name：YANG Xinyi
Department：Pharmacology
Tel: (8610) 67061033
Email: xinyiyang@imb.cams.cn
Education & Research
Education：
2000/9 – 2005/8 M. D. in Microbial and Biochemical Pharmaceutical Science, Peking Union Medical College/ Chinese Academy of Medical Sciences, Beijing, China.
1993/9 – 1998/7 B. S. in Medical Informatics, China Medical University, Shenyang, China.
Research:
2014/09 – Now Professor, Department of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China
2008/09 – 2014/08 Associate Professor, Department of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China
2005/09 – 2008/08 Assistant Professor, Department of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China
2016/04 – 2017/04 Visiting Scholar, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Stockholm, Sweden
2010/07 – 2011/10, Post-Doctoral Research Assistant, Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center (TTUHSC), Amarillo in Texas, USA
2009/11 – 2010/07 Post Doctor, Department of Pharmacology and Toxicology, The University of Alabama at Birmingham, Birmingham in Alabama, USA
Research Field：
1) Pharmacodynamics/molecular mechanisms of new antimicrobials for treatment of bacterial infections
2) Pharmacodynamics/molecular mechanisms of novel medicine for treatment of pulmonary fibrosis
Research Interests：
Dr. Yang has been engaged in research as follows: 1) pharmacodynamics and molecular mechanisms of natural products/small molecule compounds as potential antimicrobials against pathogenic bacteria, especially antibiotic-resistant bacterial strains, as well as analysis of function and drug-ability of bacteria-specific proteins as potential targets; 2) discovery of small molecule compounds with anti-pulmonary fibrosis capabilities, screening of inhibitors for signaling pathway involved in epithelial-mesenchymal transition (EMT)/myofibroblast transdifferentiation/ extracellular matrix (ECM) formation, exploration of potential targets of small molecules with anti-pulmonary fibrosis activity, and in vivo and in vitro pharmacodynamic evaluation of inhibitors for pulmonary fibrosis.
Selected Publications
1. Zhenwei Liang, Jing Pang, Xinxin Hu, Tongying Nie, Xi Lu, Xue Li, Xiukun Wang, Congran Li*, Xinyi Yang*, and Xuefu You*. Low Prevalence of mcr-1 Among Clinical Enterobacteriaceae Isolates and Co-transfer of mcr-1 and blaNDM-1 from Separate Donors.Microb Drug Resist. 2021;27(4):476-484.
2. Xue Li, Penghe Wang, Xinxin Hu, Youwen Zhang, Xi Lu, Congran Li, Tongying Nie, Guoqing Li, Xiukun Wang, Jing Pang, Yun Lu, Xinyi Yang*, Xuefu You*. The combined antibacterial effects of sodium new houttuyfonate and berberine chloride against growing and persistent methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. BMC Microbiol. 2020;20(1):317.
3. Hao Wang, Meiling Chen, Xiaohong Sang, Xuefu You, Yucheng Wang, Ian C. Paterson, Wei Hong*, Xinyi Yang*. Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage. Eur J Med Chem. 2020;191:112154.
4. Han Wu, Yu Sun, Wee Lin Wong, Jiajia Cui, Jingyang Li, Xuefu You, Lee Fah Yap, Yu Huang, Wei Hong*, Xinyi Yang*, Ian C Paterson*, Hao Wang*. The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions. Eur J Med Chem. 2020;189:112042.
5. Cheng MJ#, Yang XY#, Cao JQ, Liu C, Zhong LP, Wang Y, You XF, Li CC, Wang L, Ye WC. Isolation, Structure Elucidation, and Total Synthesis of Myrtuspirone A from Myrtus communis. Org Lett. 2019;21(6):1583-1587.
6. J Pang, C R Li, R Zhao, T Y Nie, G Q Li, X Lu, X X Hu, X K Wang, X Y Yang*, X F You*. Simplified LC-MS/MS method for quantification of IG-105, a novel tubulin ligand, and its application to the pharmacokinetic study in rats at the anticancer effective dose. Pharmazie. 2019;74(2):79-82.
7. Lu Y, Qiao F, Li Y, Sang XH, Li CR, Jiang JD, Yang XY*, You XF*.Recombinant expression and biochemical characterization of Mycobacterium tuberculosis 3Fe-4S ferredoxin Rv1786. Appl Microbiol Biotechnol. 2017;101(19):7201-7212.
8. Cong-Ran Li, Qian-Qian Zhai, Xiu-Kun Wang, Xin-Xin Hu, Guo-Qing Li, Wei-Xin Zhang, Jing Pang, Xi Lu, Hong Yuan, Mikhail Fedorovich Gordeev, Le-Tian Chen, Xin-Yi Yang*, Xue-Fu You*. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother. 2014;58(4):2418-21.
9. Lu X#, Yang X#, Li X, Lu Y, Ren Z, Zhao L, Hu X, Jiang J, You X. In vitro activity of sodium new houttuyfonate alone and in combination with oxacillin or netilmicin against methicillin-resistant Staphylococcus aureus. PLoS One. 2013 Jul 2;8(7):e68053.
10. Xinyi Yang, Wei Wang, Jiang-Jiang Qin, Ming-Hai Wang, Horrick Sharma, John K Buolamwini, Hui Wang, Ruiwen Zhang. JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. PLoS One. 2012;7(4):e34303.
11. Li CR#, Yang XY#, Lou RH, Zhang WX, Wang YM, Yuan M, Li Y, Chen HZ, Hong B, Sun CH, Zhao LX, Li ZR, Jiang JD, You XF. In Vitro Antibacterial Activity of Vertilmicin and Its Susceptibility to Modifications by the Recombinant AAC(6′)-APH(2″) Enzyme. Antimicrob Agents Chemother. 2008;52(11):3875-82.
12.Yang XY, Li CR, Lou RH, Wang YM, Zhang WX, Chen HZ, Huang QS, Han YX, Jiang JD, You XF. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China. J Med Microbiol. 2007;56(Pt 1):71-76.
